ArticleAnnals of emergency medicine2008
Annals of Emergency Medicine Journal Club. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia.
Article in Annals of emergency medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
what is already known on this topicProcalcitonin is a biomarker that appears to correlate with bacterial infection. WHAT QUESTION THIS STUDY ADDRESSED: Does a procalcitonin level add prognostic information for pneumonia patients in conjunction with scoring systems such as the Pneumonia Severity Index or CURB-65? WHAT THIS STUDY ADDS TO OUR KNOWLEDGE: Among 1,651 patients with community-acquired pneumonia in 28 US emergency departments, procalcitonin levels did not add prognostic information for most pneumonia patients. Among higher-risk groups by Pneumonia Severity Index score, low procalcitonin level predicted lower mortality. HOW THIS MIGHT CHANGE CLINICAL PRACTICE: Clinicians should continue using validated prognostic scoring systems for pneumonia. Low procalcitonin level could be considered as a factor for selected patients who would otherwise be considered high risk to be treated in a lower acuity setting.
Identifiers
18565380What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.